Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 3
1967 1
1968 1
1969 3
1970 2
1974 1
1976 1
1977 1
1978 2
1980 1
1981 1
1982 2
1983 1
1984 2
1985 3
1986 5
1987 1
1988 5
1989 4
1990 9
1991 6
1992 9
1993 7
1994 5
1995 6
1996 10
1997 4
1998 9
1999 12
2000 4
2001 10
2002 3
2003 11
2004 11
2005 10
2006 9
2007 21
2008 25
2009 35
2010 24
2011 30
2012 21
2013 20
2014 16
2015 17
2016 26
2017 18
2018 18
2019 11
2020 23
2021 33
2022 24
2023 21
2024 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

508 results

Results by year

Filters applied: . Clear all
Page 1
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Epidemiology of multiple sclerosis.
Leray E, Moreau T, Fromont A, Edan G. Leray E, et al. Among authors: moreau t. Rev Neurol (Paris). 2016 Jan;172(1):3-13. doi: 10.1016/j.neurol.2015.10.006. Epub 2015 Dec 21. Rev Neurol (Paris). 2016. PMID: 26718593
Successful treatment of JAK1-associated inflammatory disease.
Fayand A, Hentgen V, Posseme C, Lacout C, Picard C, Moguelet P, Cescato M, Sbeih N, Moreau TRJ, Zhu YYJ, Charuel JL, Corneau A, Deibener-Kaminsky J, Dupuy S, Fusaro M, Hoareau B, Hovnanian A, Langlois V, Le Corre L, Maciel TT, Miskinyte S, Miyara M, Moulinet T, Perret M, Schuhmacher MH, Rignault-Bricard R, Viel S, Vinit A, Soria A, Duffy D, Launay JM, Callebert J, Herbeuval JP, Rodero MP, Georgin-Lavialle S. Fayand A, et al. Among authors: moreau trj. J Allergy Clin Immunol. 2023 Oct;152(4):972-983. doi: 10.1016/j.jaci.2023.06.004. Epub 2023 Jun 19. J Allergy Clin Immunol. 2023. PMID: 37343845 Free article.
ARF1 prevents aberrant type I interferon induction by regulating STING activation and recycling.
Hirschenberger M, Lepelley A, Rupp U, Klute S, Hunszinger V, Koepke L, Merold V, Didry-Barca B, Wondany F, Bergner T, Moreau T, Rodero MP, Rösler R, Wiese S, Volpi S, Gattorno M, Papa R, Lynch SA, Haug MG, Houge G, Wigby KM, Sprague J, Lenberg J, Read C, Walther P, Michaelis J, Kirchhoff F, de Oliveira Mann CC, Crow YJ, Sparrer KMJ. Hirschenberger M, et al. Among authors: moreau t. Nat Commun. 2023 Nov 1;14(1):6770. doi: 10.1038/s41467-023-42150-4. Nat Commun. 2023. PMID: 37914730 Free PMC article.
[Multiple sclerosis treatments].
Moreau T. Moreau T. Soins. 2023 Mar;68(873):23-27. doi: 10.1016/j.soin.2023.02.005. Epub 2023 Mar 23. Soins. 2023. PMID: 37037639 Free article. French.
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. Kappos L, et al. N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089952 Free article. Clinical Trial.
Neuroepidemiology: From science to medical practice.
Giroud M, Dumas R, Moreau T, Béjot Y. Giroud M, et al. Among authors: moreau t. Rev Neurol (Paris). 2016 Jan;172(1):2. doi: 10.1016/j.neurol.2015.12.002. Rev Neurol (Paris). 2016. PMID: 26802450 No abstract available.
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
Jouvenot G, Courbon G, Lefort M, Rollot F, Casey R, Le Page E, Michel L, Edan G, de Seze J, Kremer L, Bigaut K, Vukusic S, Mathey G, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Collongues N, Kerbrat A; OFSEP Investigators. Jouvenot G, et al. Among authors: moreau t. JAMA Neurol. 2024 May 1;81(5):490-498. doi: 10.1001/jamaneurol.2024.0395. JAMA Neurol. 2024. PMID: 38526462
Lipid Biomarkers in Alzheimer's Disease.
Zarrouk A, Debbabi M, Bezine M, Karym EM, Badreddine A, Rouaud O, Moreau T, Cherkaoui-Malki M, El Ayeb M, Nasser B, Hammami M, Lizard G. Zarrouk A, et al. Among authors: moreau t. Curr Alzheimer Res. 2018 Feb 22;15(4):303-312. doi: 10.2174/1567205014666170505101426. Curr Alzheimer Res. 2018. PMID: 28474568 Review.
[Multiple sclerosis].
Fromont A, Moreau T. Fromont A, et al. Among authors: moreau t. Rev Prat. 2020 Apr;70(4):e125-e134. Rev Prat. 2020. PMID: 32877115 French. No abstract available.
508 results